TP53 and non-small cell lung carcinoma: Also, one of the first studies conducted by S. G. Swisher et al. also confirmed that repeated intratumoral injections of Ad-p53 were well tolerated and mediated antitumor activity in a subset of patients with advanced NSCLC [23].